NDA 022233 · Helsinn Hlthcare
Aloxi
Palonosetron Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Apr 1, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Aug 22, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
153
41 Phase 3, 11 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 22, 2008 Original approval · Type 3 - New Dosage Form LabelReviewSummary Review
1 products under this application
- ALOXI · PALONOSETRON HYDROCHLORIDE EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Palonosetron" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingPivotal-lookingCompleted
Helsinn Healthcare SAIndustry
NCT01339260 · 1,455 participants · Start Apr 2011 · Primary completion Nov 2012
Drug: Netupitant and Palonosetron; Palonosetron and 1 more · For: Chemotherapy-Induced Nausea and Vomiting
Sites: Anniston, Alabama; Muscle Shoals, Alabama; Hot Springs, Arkansas · 172 sites in all
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for CancerPivotal-lookingCompleted
Heron TherapeuticsIndustry
NCT00343460 · 1,428 participants · Start Jun 2006 · Primary completion Sep 2008
Drug: APF530; dexamethasone and 1 more · For: Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Sites: Anniston, Alabama; Glendale, Arizona; Tucson, Arizona · 52 sites in all
- Treatment of Refractory Nausea and Vomiting in Patients With Breast CancerPivotal-lookingCompleted
University of Rochester NCORP Research BaseAcademic, hospital or other
NCT03367572 · 1,363 participants · Start Apr 19, 2018 · Primary completion Apr 13, 2024
Drug: Dexamethasone; Netupitant/Palonosetron Hydrochloride and 2 more · For: Breast Carcinoma
Sites: Honolulu, Hawaii; Decatur, Illinois; New Orleans, Louisiana · 18 sites in all
- Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal SurgeryPivotal-lookingCompleted
Sixth Affiliated Hospital, Sun Yat-sen UniversityAcademic, hospital or other
NCT04853147 · 1,154 participants · Start Apr 27, 2021 · Primary completion Apr 13, 2022
Drug: palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl; palonosetron, dexamethasone, and 0.9% NaCl · For: C.Surgical Procedure; Gastrointestinal
Sites: Guangzhou, China
- Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic ChemotherapyPivotal-lookingCompleted
Taiho Pharmaceutical Co., Ltd.Industry
NCT00359567 · 1,140 participants (planned) · Start Jul 2006 · Primary completion May 2007
Drug: palonosetron; granisetron hydrochloride · For: Chemotherapy-Induced Nausea and Vomiting
Sites: 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan
Xijing HospitalAcademic, hospital or other
NCT05690802 · 1,060 participants (planned) · Start May 16, 2022 · Primary completion May 30, 2027
Drug: Palonosetron hydrochloride capsules · For: Nausea and Vomiting
Sites: Xi'an, China
- Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerPivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT05841849 · 1,028 participants (planned) · Start Jul 2023 · Primary completion Jul 2028
Drug: Aprepitant; Palonosetron and 1 more · For: Breast Cancer; Chemotherapy-induced Nausea and Vomiting
Sites: Hanzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Aloxi* (Palonosetron HCL*) · HCPCS J2469
2024 spending
$2.5M
Beneficiaries
47,725
277,642 claims
Per beneficiary
$52
2024 ASP limit $0.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $14,705,981 |
| 2021 | $7,130,973 |
| 2022 | $3,060,241 |
| 2023 | $2,955,468 |
| 2024 | $2,492,915 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, et al. · Cochrane Database Syst Rev 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Palonosetron.
Siddiqui MA, Scott LJ · Drugs 2004 · Clinical Trial, Randomized Controlled Trial
- Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis.
Patel P, Robinson PD, Wahib N, et al. · Support Care Cancer 2022 · Meta-Analysis, Systematic Review
- Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H, Abe M, Tokuyama O, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V, Adams A, Haque M, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Fosaprepitant for postoperative nausea and vomiting in patients undergoing laparoscopic gastrointestinal surgery: a randomised trial.
Huang Q, Wang F, Liang C, et al. · Br J Anaesth 2023 · Randomized Controlled Trial
Sponsor: Helsinn Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.